Hoth Therapeutics, a clinical-stage biopharmaceutical firm, is striving to meet pressing medical needs by developing innovative therapies. Among its promising treatments are HT-001, a topical solution for rash and skin issues related to epidermal growth factor receptor inhibitor therapy, as well as HT-ALZ, effective for Alzheimer's and neuroinflammatory diseases. In addition, HT-002 is a novel peptide currently under development to treat COVID-19. Hoth Therapeutics is also working on the BioLexa Platform, a drug compound platform that shows promise in eczema treatment. The company has licensed technologies from George Washington University, the University of Maryland, and others, and is collaborating with Weill Cornell Medicine to develop HT-003. Since its establishment in 2017, Hoth Therapeutics has been headquartered in New York.